Results 41 to 50 of about 12,531 (249)
Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. [PDF]
, 2019 Current pharmacological therapies for heart failure with reduced ejection fraction are largely either repurposed anti-hypertensives that blunt overactivation of the neurohormonal system or diuretics that decrease congestion.
Ahmad, T +10 more
core +2 more sources
Pulmonary Circulation, 2017 Levosimendan is an inotropic and vasodilator drug, which is known to improve cardiac function in animal models of right ventricular (RV) failure. The effects of levosimendan on oxygen consumption and myocardial efficiency in the failing RV is unknown. We
Mona S. Hansen +6 more
doaj +1 more source
Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study [PDF]
, 2008 FUNDAMENTO: A levosimendana é um novo agente inodilatador que aumenta a contratilidade cardíaca pela sensibilização ao Ca(2+) e induz vasodilatação por meio da ativação dos canais KATP/BKCa.
ALBUQUERQUE, Denilson +9 more
core +4 more sources
FEBS Open Bio, 2021 ATP‐sensitive potassium channels (KATPs) have protective effects in ischemia–reperfusion‐induced injuries and can be activated by levosimendan. This study investigated the effects of levosimendan on renal injury, inflammation, apoptosis, and survival in ...
Lei Tian +6 more
doaj +1 more source
Scandinavian SSAI clinical practice guideline on choice of inotropic agent for patients with acute circulatory failure [PDF]
, 2018 BackgroundAdult critically ill patients often suffer from acute circulatory failure and those with low cardiac output may be treated with inotropic agents.
Adamopoulos +50 more
core +3 more sources
Practical approach to diastolic dysfunction in light of the new guidelines and clinical applications in the operating room and in the intensive care [PDF]
, 2018 There is growing evidence both in the perioperative period and in the field of intensive care (ICU) on the association between left ventricular diastolic dysfunction (LVDD) and worse outcomes in patients.
Morelli, A. +3 more
core +1 more source
Use of Levosimendan in Cardiac Anesthesiology
Общая реаниматология, 2011 The authors consider the main aspects of the rational use of the novel inotropic drug levosimendan in cardiosurgical patients on the basis of the results of the trials described in the literature and on their own findings in this review.
L. A. Krichevsky +4 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Background: Aortic stenosis (AS) increases left ventricular afterload, leading to cardiac damage and heart failure (HF). Transcatheter aortic valve replacement (TAVR) is an effective therapy for AS.
Zhenyan Zhao +12 more
doaj +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source